Table 1.
Studies investigating consolidation chemotherapy
| Study | Design | N | CRT regimen | NAC regimen | Adjuvant CTx | pCR rate (%) | Compliance | R0 resection rate (%) | Surgical complication rate (%) | Survival outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| Garcia‐Aguilar49 | Phase II nonrandomized four‐arm | 259 | CRT+5FU | None | mFOLFOX (8×) | 18 | Not reported | 98 | 15 | Not reported |
| CRT+5FU | mFOLFOX6 (2×) | mFOLFOX (6×) | 25 | 82% completed NAC | 100 | 6 | Not reported | |||
| CRT+5FU | mFOLFOX6 (4×) | mFOLFOX (4×) | 30 | 81% completed NAC | 96 | 4 | Not reported | |||
| CRT+5FU | mFOLFOX6 (6×) | mFOLFOX (2×) | 36 | 77% completed NAC | 100 | 9 | Not reported | |||
| Polish II trial50 | Phase III randomized two‐arm | 515 | RT (5 × 5 Gy) | FOLFOX4 (3 cycles) | Not reported | 16 | 63% completed NAC | 77 | 29 | 3‐y DFS = 53% 3‐y OS = 73% |
| CRT+5FU / leucovorin / oxaliplatin | None | Not reported | 12 | 66% completed CRT | 71 | 25 | 3‐y DFS = 52% 3‐y OS = 65% | |||
| Gao51 | Prospective single‐arm | 36 | CRT+CAPOX | CAPOX (1×) | Not reported | 36 | 94% completed NAC | 100 | 36 | Not reported |
| Zhu52 | Phase II single‐arm | 42 | CRT+CAPOX | Cape (1×) | CAPOX (6‐8×) | 17 | 100% completed NAC | 92 | 16 | 3‐y DFS = 57% 3‐y OS = 66% |
5‐FU, 5‐fluorouracil; Cape, capecitabine; CAPOX, capecitabine/oxaliplatin; CRT, chemoradiotherapy; CTx, chemotherapy; DFS, disease‐free survival; Gy, gray; mFOLFOX6, 5‐fluorouracil, leucovorin, and oxaliplatin; NAC, neoadjuvant chemotherapy; OS, overall survival; pCR, pathological complete response; R0, microscopically clear resection; RT, radiotherapy.